Document is current
Any future updates will be listed below
-
Authors
Chiappella, Annalisa http://orcid.org/0000-0002-2977-0098
Casadei, Beatrice
Chiusolo, Patrizia http://orcid.org/0000-0002-1355-1587
Di Rocco, Alice
Ljevar, Silva
Magni, Martina
Angelillo, Piera
Barbui, Anna Maria
Cutini, Ilaria
Dodero, Anna
Bonifazi, Francesca http://orcid.org/0000-0003-1544-9911
Tisi, Maria Chiara
Bramanti, Stefania
Musso, Maurizio
Farina, Mirko http://orcid.org/0000-0002-2980-9028
Martino, Massimo
Novo, Mattia http://orcid.org/0000-0002-5127-3653
Grillo, Giovanni
Patriarca, Francesca
Zacchi, Giulia
Krampera, Mauro http://orcid.org/0000-0002-7280-2040
Pennisi, Martina
Galli, Eugenio
Martelli, Maurizio
Ferreri, Andrés J. M. http://orcid.org/0000-0001-9606-6124
Ferrari, Silvia
Saccardi, Riccardo
Bermema, Anisa
Guidetti, Anna
Miceli, Rosalba
Zinzani, Pier Luigi http://orcid.org/0000-0002-2112-2651
Corradini, Paolo http://orcid.org/0000-0002-9186-1353
- License Information
-
More Information
Article History
Received: 7 November 2023
Revised: 27 February 2024
Accepted: 28 February 2024
First Online: 8 March 2024
Competing interests
: AC - Advisory boards: Gilead-Sciences, Ideogen, Roche, SecuraBIO, Takeda; honoraria for lectures/educational events: Abbvie, Eli Lilly, Gilead-Sciences, Incyte, Janssen-Cilag, Novartis, Takeda. BC - Advisory boards and honoraria for lectures/educational events: Kite Gilead, Novartis. FB - Advisory boards and honoraria for lectures/educational events: Kite Gilead, Novartis. SB - Speaker bureau: Bristol-Myers Squibb, Gilead, Novartis; advisory board: Novartis; Travel accommodation: Novartis, Roche. AJMF has received speaker fees from Adienne, AstraZeneca, Bristol-Myers Squibb, Gilead, Novartis, and Roche; was a member of advisory boards of Abbvie, AstraZeneca, Bristol-Myers Squibb, Genmab, Gilead, Incyte, Juno, Novartis, PletixaPharm, and Roche; and currently receives research grants from Abbvie, Amgen, ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb, Genmab, Gilead, Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, Pfizer, Pharmacyclics, PletixaPharm, Protherics, Roche, and Takeda; and holds patents on NGR-hTNF-alfa in brain tumours and NGR-hTNF/R-CHOP in relapsed or refractory PCNSL and SNGR-hTNF in brain tumors. PLZ – Consultant: MSD, Eusapharma, Novartis; Advisory boards: ADC Therapeutics, Astrazeneca, BeiGene, BMS, Celltrion, Eusapharma, Gilead, Incyte, Janssen-Cilag, KyowaKirin, MSD, Novartis, Roche, Sandoz, SecuraBio, Servier, Takeda; speakers bureau: Astrazeneca, Beigene, BMS, Celltrion, Eusapharma, Gilead, Incyte, Janssen-Cilag, Kyowa-Kirin, MSD, Novartis, Roche, Servier, Takeda. PCo - Advisory boards: AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda; honoraria for lectures: AbbVie, Amgen, Celgene, Gilead/Kite, Janssen, Novartis, Roche, Sanofi, Takeda. The other authors declare that they have no conflict of interest.
